New toxicity testing of PQ grass allergy immunotherapy to support product development
- 23 June 2019
- journal article
- research article
- Published by Wiley in Journal of Applied Toxicology
- Vol. 39 (10) , 1462-1469
Abstract
PQ Grass represents an allergen‐specific immunotherapy for pre‐seasonal treatment of patients with seasonal allergic rhinitis (or rhinoconjunctivitis) with or without mild‐to‐moderate bronchial asthma. It consists of a native pollen extract for 13 grass species, chemically modified with glutaraldehyde, and adsorbed to l‐tyrosine in a microcrystalline form with addition of the adjuvant Monophosphoryl Lipid A (MPL®). Previous non‐clinical safety testing, including rat repeat dose toxicity in adult and juvenile animals, rat reproductive toxicity and rabbit local tolerance studies showed no safety findings of concern. A new Good Laboratory Practice compliant rat subcutaneous repeat dose toxicity study to evaluate a higher clinical dose and modified posology (once every 2 weeks for 13 weeks) showed no signs of toxicity. As seen in previous studies, relatively minor, immunostimulatory effects were seen such as reversible increased white cell count (notably neutrophils), increased globulin level (resulting in decreased A/G ratio) and increased fibrinogen as well as minor dose site reaction in the form of inflammatory cell infiltrate. These findings are likely due to the immunostimulatory nature of MPL and/or the presence of l‐tyrosine within the adjuvanted vaccine. This new toxicity study with PQ Grass therefore supports longer posology with higher dose levels.Keywords
This publication has 27 references indexed in Scilit:
- Reproduction and juvenile animal toxicology studies in the rat with a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergyReproductive Toxicology, 2011
- A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergyJournal of Applied Toxicology, 2011
- Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvantCellular and Molecular Life Sciences, 2008
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- Pollinex® Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of ragweed pollen allergyJournal of Applied Toxicology, 2007
- Immunoregulation by targeting T cells in the treatment of allergy and asthmaCurrent Opinion in Immunology, 2006
- Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergyJournal of Applied Toxicology, 2004
- Review of L‐tyrosine confirming its safe human use as an adjuvantJournal of Applied Toxicology, 2002
- Allergen immunotherapy: Therapeutic vaccines for allergic diseases A WHO position paperJournal of Allergy and Clinical Immunology, 1998
- Chemical Modification of Crude Timothy Grass Pollen ExtractInternational Archives of Allergy and Immunology, 1977